BioCentury | Oct 3, 2020
Emerging Company Profile

Emmecell: magnetic cell therapy for eye diseases

Emmecell emerged from stealth last week with a clinic-ready cell therapy for corneal edema that could address mild disease and offer a less invasive alternative to corneal transplant surgery in patients...
BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

Among four new biotech listings Friday, three priced upsized IPOs that each delivered more than $200 million in proceeds, but none of the quartet enjoyed the kind of satisfying first-day pop other biotechs have had...
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

June has already seen 13 biopharmas raise more than a total of $4.7 billion from NASDAQ IPOs, and biotechs are continuing to line up for public market debuts (see “Biotech IPOs on NASDAQ Maintain Momentum”...
BioCentury | Jun 26, 2020
Finance

June 25 Quick Takes: Chi-Med rakes in $100M; plus bank rules rolled back, newco DeCART has June ties and more

Chi-Med raises $100M private placement Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) raised $100 million Thursday in a private placement to General Atlantic through the sale of 4 million ADSs at $25. The price matches its...
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

Next-generation checkpoint inhibitors will take the limelight at the 2020 virtual ASCO meeting, with all eyes on TIGIT as the first to back up the noise with data. Genentech is poised to present Phase II...
BioCentury | Apr 1, 2020
Finance

Reversing course on IPO plans, iTeos draws $125M in private round with crossovers

With two programs having entered the clinic since the company’s series B round, iTeos chose to raise another large private round rather than seek to tap the public markets as it had expected, drawing a...
BioCentury | Sep 27, 2019
Politics, Policy & Law

Trump administration to modernize flu vaccines via government buying power

The U.S. government is laying plans to harness its buying power and applied research capabilities to pull influenza vaccine development and manufacturing into the 21st century. The goals are to enhance protection against seasonal flu,...
BioCentury | Mar 20, 2019
Company News

Enterome, Dana-Farber partner on microbiome-derived mimics of tumor antigens

Enterome and Dana-Farber Cancer Institute partnered to validate the use of microbiome-derived antigens for cancer immunotherapies, expanding on the company's own discovery of onco-mimics, or bacterial antigens that mimic tumor antigens. Enterome Bioscience S.A. (Paris,...
BioCentury | Mar 15, 2019
Company News

Another setback for Spectrum's remaining pipeline after Rolontis BLA withdrawal

...Divesting Marketed Products to Focus on Late-Stage Programs" ). Along with Rolontis, Spectrum's pipeline comprises apaziquone...
...Friday’s news sent shares $0.30 lower to $9.98. Elizabeth S. Eaton, Staff Writer apaziquone (eoquin, EO9, Neoquin, Qapzola) LAPS-GCSF...
BioCentury | Jun 22, 2018
Financial News

Oncology play iTeos raises $75M, outlines clinical plans

iTeos Therapeutics S.A. (Gosselies, Belgium) raised $75 million on June 19 in a series B round led by MPM Capital. Also participating in the round were HBM Partners, 6 Dimensions Capital, Curative Ventures and SFPI...
Items per page:
1 - 10 of 211